- Home
- FMAO vs RIGL Comparison
FMAO vs RIGL Comparison
Compare FMAO & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FMAO
- RIGL
- Stock Information
- Founded
- FMAO 1897
- RIGL 1996
- Country
- FMAO United States
- RIGL United States
- Employees
- FMAO N/A
- RIGL N/A
- Industry
- FMAO Savings Institutions
- RIGL Biotechnology: Pharmaceutical Preparations
- Sector
- FMAO Finance
- RIGL Health Care
- Exchange
- FMAO Nasdaq
- RIGL Nasdaq
- Market Cap
- FMAO 356.9M
- RIGL 335.5M
- IPO Year
- FMAO N/A
- RIGL 2000
- Fundamental
- Price
- FMAO $26.13
- RIGL $38.85
- Analyst Decision
- FMAO
- RIGL Buy
- Analyst Count
- FMAO 0
- RIGL 5
- Target Price
- FMAO N/A
- RIGL $38.20
- AVG Volume (30 Days)
- FMAO 21.8K
- RIGL 995.6K
- Earning Date
- FMAO 10-29-2025
- RIGL 08-05-2025
- Dividend Yield
- FMAO 3.34%
- RIGL N/A
- EPS Growth
- FMAO 38.39
- RIGL N/A
- EPS
- FMAO 2.16
- RIGL 5.43
- Revenue
- FMAO $108,632,000.00
- RIGL $267,921,000.00
- Revenue This Year
- FMAO $1.60
- RIGL $59.93
- Revenue Next Year
- FMAO $13.77
- RIGL N/A
- P/E Ratio
- FMAO $12.26
- RIGL $7.15
- Revenue Growth
- FMAO 13.86
- RIGL 105.62
- 52 Week Low
- FMAO $20.88
- RIGL $12.66
- 52 Week High
- FMAO $34.15
- RIGL $43.72
- Technical
- Relative Strength Index (RSI)
- FMAO 58.09
- RIGL 68.57
- Support Level
- FMAO $24.60
- RIGL $39.00
- Resistance Level
- FMAO $27.01
- RIGL $42.08
- Average True Range (ATR)
- FMAO 0.81
- RIGL 2.32
- MACD
- FMAO 0.23
- RIGL -0.37
- Stochastic Oscillator
- FMAO 89.44
- RIGL 53.26
About FMAO Farmers & Merchants Bancorp Inc.
Farmers & Merchants Bancorp Inc is a holding company based in Ohio. The company is engaged in general commercial banking business. The activities of the company include commercial, agricultural and residential mortgages as well as consumer and credit card lending activities.
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.